U OF U HOSPITALS & CLINICS
- Type
- Teaching hospital
- Where
- Salt Lake City, UT
- Medicare CCN
- 460009
- Received
- $37,145,780 in 3,756 records, 2025 ($3,697,329 general, $33,448,451 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 239 | $3,697,329 |
| 2025 | Research payment | 3,517 | $33,448,451 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3,517 | $33,448,451 |
| Grant | 60 | $1,668,809 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 34 | $771,352 |
| Space rental or facility fees (teaching hospital only) | 92 | $538,104 |
| Consulting Fee | 9 | $429,855 |
| Royalty or License | 5 | $128,925 |
| Education | 20 | $93,706 |
| Long term medical supply or device loan | 3 | $36,709 |
| Debt forgiveness | 10 | $13,745 |
| Gift | 3 | $9,500 |
| Charitable Contribution | 3 | $6,620 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $323,216 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $296,450 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $197,706 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2025 |
| 2025-12-31 | Eli Lilly and Company | $105,993 | Research payment | Cash or cash equivalent | A PHASE 1A/1B TRIAL OF LY3962673 IN PARTICIPANTS WITH KRAS G12D-MUTANT SOLID TUMORS | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $94,409 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $55,389 | Research payment | In-kind items and services | PADCEV Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an | 2025 |
| 2025-12-31 | Balt USA, LLC | $37,410 | Research payment | Cash or cash equivalent | The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM) | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $36,266 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $34,811 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a M | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $31,128 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $30,157 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an | 2025 |
| 2025-12-31 | JAZZ PHARMACEUTICALS INC. | $24,887 | Research payment | Cash or cash equivalent | Evaluation of selected test items for anticonvulsant activity in mouse scPTZ (85mg/kg s.c.) model of myoclonic generalis | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $22,239 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $21,745 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $17,540 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $16,351 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2025 |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $16,057 | Research payment | In-kind items and services | Multitom Rax Device, DI - X-Ray Products | Assessment of novel 3D imaging features of Multitom Rax | 2025 |
| 2025-12-31 | JAZZ PHARMACEUTICALS INC. | $13,222 | Research payment | Cash or cash equivalent | ZIIHERA Drug, HEMATOLOGY/ONCOLOGY | I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $10,300 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2025 |
| 2025-12-31 | Sumitomo Pharma America, Inc. | $10,199 | Research payment | In-kind items and services | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth | 2025 | |
| 2025-12-31 | PFIZER INC. | $9,981 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $8,536 | Education | In-kind items and services | IMAGE 1 Device, T-VIDEOIMAGING | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $7,126 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $6,608 | Education | In-kind items and services | HOPKINS Device, K-LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $6,450 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $6,425 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $5,966 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $5,966 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | BioFire Diagnostics, LLC | $5,350 | Research payment | In-kind items and services | BIOFIRE SPOTFIRE Module Device, Diagnostics | SpotFire STI Prospective Study | 2025 |
| 2025-12-31 | BioFire Diagnostics, LLC | $5,350 | Research payment | In-kind items and services | BIOFIRE SPOTFIRE Module Device, Diagnostics | SpotFire STI Prospective Study | 2025 |
| 2025-12-31 | PFIZER INC. | $2,938 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA | 2025 | |
| 2025-12-31 | Stryker Corporation | $2,739 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | ABBVIE INC. | $1,656 | Research payment | In-kind items and services | VYALEV Drug, NEUROSCIENCE | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure | 2025 |
| 2025-12-31 | HemoSonics LLC | $1,500 | Research payment | In-kind items and services | QUNATRA QPLUS SYSTEM Device, HEMATOLOGY | Evaluation of the Clinical Performance of the Quantra System with the QStat Cartridge in Obstetric Patients | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $1,231 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $1,141 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | Abbott Laboratories | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INFINITY Device, Structural Heart | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $809 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $681 | Education | In-kind items and services | n.a. Device, D-ENT | 2025 | |
| 2025-12-31 | ABBVIE INC. | $600 | Research payment | In-kind items and services | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combin | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $333 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | $313 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Idiopathic Pulmonary Fibrosis Prospective Outcome Registry | 2025 |
| 2025-12-31 | ABBVIE INC. | $296 | Research payment | In-kind items and services | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | 2025 | |
| 2025-12-31 | Stryker Corporation | $161 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | $131 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Idiopathic Pulmonary Fibrosis Prospective Outcome Registry | 2025 |
| 2025-12-31 | Stryker Corporation | $130 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $120 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $120 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | Teleflex LLC | $99 | Long term medical supply or device loan | Cash or cash equivalent | DEKNATEL Device, SURGICAL | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $63 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA- | 2025 |
| 2025-12-30 | PharmaEssentia USA Corporation | $11,880 | Research payment | Cash or cash equivalent | P1101ET | 2025 | |
| 2025-12-30 | Synthes GmbH | $6,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | FLEXABILITY Device, Structural Heart | NCT05839873--Abbott Ventricular Tachycardia PAS | 2025 |
| 2025-12-29 | Janssen Research & Development, LLC | $119,809 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-29 | Janssen Research & Development, LLC | $13,592 | Research payment | Cash or cash equivalent | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cance | 2025 | |
| 2025-12-29 | Medical Device Business Services, Inc. | $4,825 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-29 | Janssen Research & Development, LLC | $3,406 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred | 2025 | |
| 2025-12-27 | Medacta USA, Inc. | $2,376 | Research payment | Cash or cash equivalent | GMK Hinge Device, Devices | Midterm Survival of the Medacta GMK Hinge in Primary and Revision Total Knee Arthroplasty | 2025 |
| 2025-12-26 | SEAGEN INC. | $12,390 | Research payment | Cash or cash equivalent | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48A | 2025 | |
| 2025-12-26 | PFIZER INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-12-26 | Janssen Research & Development, LLC | $1,224 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-12-26 | Janssen Research & Development, LLC | $697 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-12-25 | PFIZER INC. | $17,365 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $6,242 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $4,565 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | Edwards Lifesciences Corporation | $3,000 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2025 | |
| 2025-12-24 | PFIZER INC. | $2,075 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,952 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | CSL Behring | $36 | Research payment | In-kind items and services | HEMGENIX Biological, Hematology | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ | 2025 |
| 2025-12-23 | PharmaEssentia USA Corporation | $13,686 | Research payment | Cash or cash equivalent | BESREMI Drug, Oncology | A22-203 | 2025 |
| 2025-12-23 | ABBVIE INC. | $6,265 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-23 | Scientia Vascular | $5,500 | Research payment | Cash or cash equivalent | MO-ADAPT | 2025 | |
| 2025-12-23 | BeOne Medicines Ltd. | $4,313 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax | 2025 |
| 2025-12-23 | ABBVIE INC. | $1,830 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-23 | ABBVIE INC. | $1,830 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-23 | ABBVIE INC. | $1,830 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-23 | ABBVIE INC. | $467 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-22 | Janssen Research & Development, LLC | $16,361 | Research payment | Cash or cash equivalent | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic A | 2025 | |
| 2025-12-22 | Janssen Research & Development, LLC | $13,310 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi | 2025 | |
| 2025-12-22 | Janssen Research & Development, LLC | $7,143 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-12-22 | Janssen Research & Development, LLC | $6,370 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric | 2025 |
| 2025-12-22 | SANOFI US SERVICES INC. | $5,617 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-22 | Janssen Research & Development, LLC | $4,862 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2025 | |
| 2025-12-22 | La Jolla Pharmaceutical Company | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | GIAPREZA Drug, EMERGENT HYPOTENSION | 2025 | |
| 2025-12-19 | Janssen Scientific Affairs, LLC | $250,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-19 | ADC THERAPEUTICS AMERICA, INC. | $24,099 | Research payment | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | IIT_EPPERLA_ADCT-402-1 | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $6,515 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 | |
| 2025-12-19 | ADC THERAPEUTICS AMERICA, INC. | $4,550 | Research payment | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | IIT_EPPERLA_ADCT-402-1 | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $3,296 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS W | 2025 |
| 2025-12-19 | ABBVIE INC. | $2,666 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $2,666 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $2,472 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $2,472 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $2,472 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | Stryker Corporation | $2,113 | Research payment | Cash or cash equivalent | TORNIER PERFORM REVERSED AUGMENTED GLENOID Device, BONE SUBSTITUTE | PERFORM HUMERAL SYSTEM STUDY (PHS) | 2025 |
| 2025-12-19 | ABBVIE INC. | $1,725 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $1,620 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $1,620 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $1,620 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | PFIZER INC. | $1,400 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY | 2025 |
| 2025-12-19 | ABBVIE INC. | $675 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $675 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $675 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $554 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $554 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $554 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ADC THERAPEUTICS AMERICA, INC. | $500 | Research payment | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | IIT_EPPERLA_ADCT-402-1 | 2025 |
| 2025-12-19 | ABBVIE INC. | $387 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-19 | ABBVIE INC. | $387 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously ( | 2025 | |
| 2025-12-18 | Janssen Scientific Affairs, LLC | $68,850 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | Longitudinal Multi-Center Chart Review Data Repository For Multiple Myeloma | 2025 |
| 2025-12-18 | Alcon Research LLC | $29,625 | Research payment | Cash or cash equivalent | HYDRUS Microstent Device, Ophthalmology | 3 Year Outcomes of Combined Hydrus Microstent with iTrack Canaloplasty | 2025 |
| 2025-12-18 | Glaukos Corporation | $18,900 | Research payment | Cash or cash equivalent | PRESERFLO MicroShunt Device, Ophthalmology | Prospective, Multicenter Study of PRESERFLOMicroShunt in Subjects with Primary Open-AngleGlaucoma Who Have Failed Previo | 2025 |
| 2025-12-18 | Genentech, Inc. | $13,852 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients | 2025 |
| 2025-12-18 | SANOFI US SERVICES INC. | $10,785 | Research payment | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-12-18 | Boston Scientific Corporation | $10,000 | Grant | Cash or cash equivalent | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-18 | SANOFI US SERVICES INC. | $1,905 | Research payment | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-12-18 | Janssen Research & Development, LLC | $1,525 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred | 2025 | |
| 2025-12-18 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | Becton, Dickinson and Company | $120 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-17 | Ionis Pharmaceuticals, Inc. | $71,528 | Research payment | Cash or cash equivalent | TRYNGOLZA Drug, CARDIOLOGY | Olezarsen for treatment of Familial Chylomicromenia syndrome | 2025 |
| 2025-12-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25,120 | Research payment | Cash or cash equivalent | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administere | 2025 | |
| 2025-12-17 | PFIZER INC. | $24,451 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY | 2025 |
| 2025-12-17 | Synthes GmbH | $22,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Sumitomo Pharma America, Inc. | $16,321 | Research payment | Cash or cash equivalent | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS | 2025 | |
| 2025-12-17 | Sumitomo Pharma America, Inc. | $13,596 | Research payment | Cash or cash equivalent | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS | 2025 | |
| 2025-12-17 | Sumitomo Pharma America, Inc. | $13,596 | Research payment | Cash or cash equivalent | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS | 2025 | |
| 2025-12-17 | Sumitomo Pharma America, Inc. | $13,345 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth | 2025 | |
| 2025-12-17 | Sumitomo Pharma America, Inc. | $11,486 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth | 2025 | |
| 2025-12-17 | Sumitomo Pharma America, Inc. | $8,000 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth | 2025 | |
| 2025-12-17 | Synthes GmbH | $7,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Sumitomo Pharma America, Inc. | $7,006 | Research payment | Cash or cash equivalent | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS | 2025 | |
| 2025-12-17 | PFIZER INC. | $3,421 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Daiichi Sankyo Inc. | $2,685 | Research payment | Cash or cash equivalent | DS3939-077 | 2025 | |
| 2025-12-17 | Daiichi Sankyo Inc. | $1,184 | Research payment | Cash or cash equivalent | DS3939-077 | 2025 | |
| 2025-12-17 | Medtronic, Inc. | $921 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2025 |
| 2025-12-17 | Sumitomo Pharma America, Inc. | $280 | Research payment | Cash or cash equivalent | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS | 2025 | |
| 2025-12-17 | Sumitomo Pharma America, Inc. | $120 | Research payment | Cash or cash equivalent | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS | 2025 | |
| 2025-12-17 | Abbott Laboratories | $99 | Research payment | Cash or cash equivalent | I-STAT Device, Point of Care | ISM2404009A--Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury | 2025 |
| 2025-12-16 | Boston Scientific Corporation | $48,354 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_NMD | IMPROVE | 2025 |
| 2025-12-16 | Incyte Corporation | $18,721 | Research payment | Cash or cash equivalent | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 | |
| 2025-12-16 | BeOne Medicines USA, Inc. | $6,370 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients W | 2025 |
| 2025-12-16 | PFIZER INC. | $6,112 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA | 2025 | |
| 2025-12-16 | PFIZER INC. | $5,890 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY | 2025 |
| 2025-12-16 | PFIZER INC. | $5,696 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2025 |
| 2025-12-16 | Janssen Research & Development, LLC | $1,901 | Research payment | Cash or cash equivalent | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial C | 2025 | |
| 2025-12-16 | PTC Therapeutics, Inc. | $117 | Research payment | Cash or cash equivalent | A PHASE 3 OPEN-LABEL STUDY OF PTC923 (SEPIAPTERIN) IN PHENYLKETONURIA | 2025 | |
| 2025-12-15 | Merck Sharp & Dohme LLC | $299,879 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2025 |
| 2025-12-15 | Merck Sharp & Dohme LLC | $257,224 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an | 2025 |
| 2025-12-15 | Merck Sharp & Dohme LLC | $161,327 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2025 |
| 2025-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,410 | Research payment | Cash or cash equivalent | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administere | 2025 | |
| 2025-12-15 | Edwards Lifesciences Corporation | $12,630 | Research payment | Cash or cash equivalent | COMPASSION S3 2015-01 | 2025 | |
| 2025-12-15 | Janssen Research & Development, LLC | $7,915 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi | 2025 | |
| 2025-12-15 | Janssen Research & Development, LLC | $6,108 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric | 2025 |
| 2025-12-15 | Novo Nordisk Inc | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,371 | Research payment | Cash or cash equivalent | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administere | 2025 | |
| 2025-12-15 | Janssen Research & Development, LLC | $1,926 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | $561 | Research payment | Cash or cash equivalent | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (A | 2025 | |
| 2025-12-12 | Janssen Research & Development, LLC | $4,300 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-12-12 | Janssen Research & Development, LLC | $1,750 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-12-11 | Sumitomo Pharma America, Inc. | $255,865 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth | 2025 | |
| 2025-12-11 | Incyte Corporation | $26,447 | Research payment | Cash or cash equivalent | A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United St | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $14,645 | Research payment | Cash or cash equivalent | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 | |
| 2025-12-11 | Incyte Corporation | $10,579 | Research payment | Cash or cash equivalent | A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United St | 2025 | |
| 2025-12-11 | BeOne Medicines Ltd. | $2,672 | Research payment | In-kind items and services | A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, | 2025 | |
| 2025-12-11 | Ipsen Pharma SAS | $2,516 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Deve | 2025 |
| 2025-12-11 | Edwards Lifesciences Corporation | $2,180 | Research payment | Cash or cash equivalent | ALTERRA Post-Approval Study 2021-11 | 2025 | |
| 2025-12-11 | Ferring Pharmaceuticals AS | $2,150 | Research payment | Cash or cash equivalent | ADSTILADRIN Biological, ONCOLOGY | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | 2025 |
| 2025-12-11 | Syndax Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | EXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCI | 2025 |
| 2025-12-11 | Ferring Pharmaceuticals AS | $1,000 | Research payment | Cash or cash equivalent | ADSTILADRIN Biological, ONCOLOGY | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | 2025 |
| 2025-12-11 | Sumitomo Pharma America, Inc. | $0 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth | 2025 | |
| 2025-12-10 | Boston Scientific Corporation | $362,323 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-10 | Alexion Pharmaceuticals, Inc. | $24,925 | Research payment | Cash or cash equivalent | STRENSIQ Biological, Rare Disease | A Prospective Observational Sub Study of the Global Hypophosphatasia Registry to Evaluate the Potential Risk of Immune M | 2025 |
| 2025-12-10 | ABBVIE INC. | $18,241 | Research payment | Cash or cash equivalent | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 | |
| 2025-12-10 | Merck Sharp & Dohme LLC | $8,133 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i | 2025 |
| 2025-12-10 | Eidos Therapeutics, Inc. | $3,240 | Research payment | Cash or cash equivalent | Attruby Drug, Cardiomyopathy | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P | 2025 |
| 2025-12-10 | Abbott Laboratories | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INFINITY Device, Structural Heart | 2025 | |
| 2025-12-10 | Eidos Therapeutics, Inc. | $2,500 | Research payment | Cash or cash equivalent | Attruby Drug, Cardiomyopathy | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P | 2025 |
| 2025-12-10 | Draeger Medical Systems, Inc | $1,500 | Education | Cash or cash equivalent | Evita V800 Device, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-10 | Takeda Pharmaceuticals U.S.A., Inc. | $395 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 | |
| 2025-12-10 | Eidos Therapeutics, Inc. | $270 | Research payment | Cash or cash equivalent | Attruby Drug, Cardiomyopathy | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P | 2025 |
| 2025-12-09 | BeOne Medicines Ltd. | $282,156 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax | 2025 |
| 2025-12-09 | BeOne Medicines USA, Inc. | $57,175 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients W | 2025 |
| 2025-12-09 | Merck Sharp & Dohme LLC | $34,843 | Research payment | Cash or cash equivalent | ENFLONSIA Drug, INFECTIOUS DISEASE | The Use of Antibiotics for RSV in Hospitalized Children <2 Years of Age | 2025 |
| 2025-12-09 | Medtronic, Inc. | $9,000 | Research payment | Cash or cash equivalent | PISCES-QUAD PLUS Device, Spinal Cord Neurostimulation | PSR-PSTM | 2025 |
| 2025-12-09 | ABBVIE INC. | $3,975 | Research payment | Cash or cash equivalent | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | 2025 | |
| 2025-12-08 | ACADIA Pharmaceuticals Inc | $21,938 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-12-08 | Visby Medical, Inc. | $10,000 | Royalty or License | Cash or cash equivalent | Visby Medical Sexual Health Click Test Device, Sexual Health Test | 2025 | |
| 2025-12-08 | ABBVIE INC. | $7,792 | Research payment | Cash or cash equivalent | Phase 1b Study to Investigate ABBV-CLS-7262s Safety Tolerability & Pharmacokinetics in Vanishing White Matter Patients | 2025 | |
| 2025-12-08 | GENZYME CORPORATION | $2,814 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropath | 2025 | |
| 2025-12-08 | Liquidia Technologies, Inc. | $2,000 | Research payment | Cash or cash equivalent | YUTREPIA Drug, Pulmonary | A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil | 2025 |
| 2025-12-08 | Liquidia Technologies, Inc. | $2,000 | Research payment | Cash or cash equivalent | YUTREPIA Drug, Pulmonary | A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil | 2025 |
| 2025-12-08 | Liquidia Technologies, Inc. | $1,836 | Research payment | Cash or cash equivalent | YUTREPIA Drug, Pulmonary | A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil | 2025 |
| 2025-12-08 | Liquidia Technologies, Inc. | $1,836 | Research payment | Cash or cash equivalent | YUTREPIA Drug, Pulmonary | A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil | 2025 |
The latest 200 records of 3,756.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Salt Lake City, UT, county Salt Lake County, UT, state Utah; placed by its city name.
| Measure | Place (city or town) Salt Lake City, UT | County Salt Lake County, UT | State Utah |
|---|---|---|---|
| Population B01003 | 208,007 | 1,196,523 | 3,392,331 |
| Population, 2020 census P1 | 199,723 | 1,185,238 | 3,271,616 |
| Median age B01002 | 32.9 | 34.0 | 32.0 |
| Under 18 B01001 | 16.4% | 25.3% | 27.8% |
| 65 and over B01001 | 12.5% | 11.9% | 11.9% |
| Households B11001 | 92,652 | 426,245 | 1,124,822 |
| Foreign born B05002 | 14.9% | 13.5% | 8.9% |
| Median household income B19013 | $75,090 | $97,494 | $95,166 |
| Median family income B19113 | $109,291 | $116,682 | $109,675 |
| Per capita income B19301 | $51,173 | $45,106 | $40,873 |
| Poverty rate B17001 | 13.6% | 8.1% | 8.5% |
| Unemployment rate B23025 | 4.2% | 3.8% | 3.6% |
| Civilian labor force B23025 | 129,830 | 670,900 | 1,778,106 |
| Mean commute (minutes) B08013 | 19.5 | 22.3 | 22.1 |
| Bachelor's degree or higher B15003 | 51.5% | 39.4% | 37.7% |
| Housing units B25001 | 101,188 | 449,662 | 1,223,468 |
| Owner-occupied B25003 | 45.8% | 66.1% | 70.2% |
| Renters B25003 | 54.2% | 33.9% | 29.8% |
| Median home value B25077 | $539,500 | $525,700 | $489,400 |
| Median gross rent B25064 | $1,414 | $1,592 | $1,496 |
| White, not Hispanic B03002 | 64.4% | 66.6% | 74.7% |
| Black B03002 | 2.3% | 1.7% | 1.1% |
| Hispanic or Latino B03002 | 20.8% | 20.6% | 15.9% |
| Asian B03002 | 4.9% | 4.2% | 2.4% |
| American Indian and Alaska Native B03002 | 0.5% | 0.5% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Salt Lake City, UT.
Comments